Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

common-default.jpeg

Terms / Notices

Cookies

Privacy Policy

Reporting Hotline

Attorney Advertising

Alumni

  Linkedin

MoFo LinkedIN

  Facebook

MoFo Facebook

YouTube

MoFo Youtube

Morrison Foerster - Footer

Beyond the LDT Final Rule: A Renaissance in Diagnostics Innovation

You have not solved the recaptcha challenge yet or session expired, try again.

Email Disclaimer

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

Morrison Foerster lawyer Atiq Chowdhury will moderate the session “Beyond the LDT Final Rule: A Renaissance in Diagnostics...

Morrison Foerster lawyer Atiq Chowdhury will moderate the session “Beyond the LDT Final Rule: A Renaissance in Diagnostics Innovation,” at Food & Drug Law Institute’s 2025 Annual Conference on May 16, 2025, from 11:00 a.m. to 12:00 p.m. EST. This session will explore the rapidly evolving landscape of diagnostics, from AI-driven IVDs to the latest advancements in LDTs, focusing on how regulatory frameworks are adapting to these innovations.For more information about Food & Drug Law Institute’s 2025 Annual Conference and to participate in this event, please visit the <a href="https://portal.fdli.org/s/lt-event?id=a1URn000001AIazMAG#/Overview" target="_blank">registration page</a>.<hr>

Sign Up

Atiq Chowdhury is an associate in the FDA + Healthcare Regulatory and Compliance practice, where he advises FDA-regulated companies on a wide range of regulatory, enforcement, and compliance matters. He counsels pharmaceutical, medical device, and food companies on FDA regulatory requirements, fraud and abuse issues, states’ corporate practice of medicine and licensing matters. Atiq focuses on assisting clients in the diagnostics, software as a medical device, mobile medical applications, and medical technology fields in becoming compliant with the Federal Food, Drug, and Cosmetic Act and the Clinical Laboratory Improvement Amendments. Prior to joining Morrison Foerster, Atiq practiced at other leading international law firms. For more than a decade, he also worked in reviewer and policy roles at the U.S. Food and Drug Administration (FDA). In these roles, he reviewed Premarket Approval notifications and applications, Investigational Device Exemptions, Q-Submission requests, and promotional and compliance issues, and contributed to guidance documents and other agency policy priorities. He also served as a Commissioned Corps Officer in the U.S. Public Health Service (PHS) for nearly a decade. While at the FDA, Atiq was honored by the FDA Center for Devices and Radiological Health (CDRH) with the Special Recognition Award for MDUFA III Assessment and Implementation and the Excellence in Compliance and Enforcement Award. He also received Commendation and Citation medals from the PHS for his contributions to approving and clearing first-of-their-kind diagnostic and therapeutic devices.Atiq’s experience has included, for example:<ul><li>Assisting clients with interactions between FDA and other global health authorities related to drug and device submissions (e.g., Investigational New Drugs, New Drug Applications, Q-Submissions, 510k applications, Investigational Device Exemptions, De Novo submissions, and Premarket Approval applications).</li><li>Advising clients on FDA regulations and global regulatory strategies related to the development of drug, device, and combination product marketing applications which include software applications, companion diagnostics, diagnostic tests, biomarkers, and digital health tools.</li><li>Advising medical device and pharmaceutical facilities on preparation for FDA inspections or responding to FDA Form 483 observations, import alerts, and warning letters, as well as developing site remediation work plans.</li><li>Performing gap assessments for device and drug manufacturers across a range of quality systems, including complaint handling, corrective and preventive actions, good documentation practices, supplier management, and adverse event safety reporting.</li><li>Supporting internal investigations concerning alleged cGMP/QSR compliance violations at FDA-regulated manufacturing facilities based in the United States, Europe, and Asia.</li><li>Representing and advising large healthcare and life sciences companies, as well as small biotech and medtech companies, on acquisitions, mergers, joint ventures, and other arrangements.</li></ul>

Atiq Chowdhury

Associate

Life Sciences + Healthcare

FDA + Healthcare Regulatory and Compliance

Beyond the LDT Final Rule: A Renaissance in Diagnostics Innovation

16 May 2025 11:00 AM - 12:00 PM EDT